These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26745108)

  • 21. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison Study of Self-Sampled and Physician-Sampled Specimens for High-Risk Human Papillomavirus Test and Cytology.
    Satake H; Inaba N; Kanno K; Mihara M; Takagi Y; Kondo N; Sagae S
    Acta Cytol; 2020; 64(5):433-441. PubMed ID: 32396902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of human papillomavirus in male and female urine by electrochemical DNA chip and PCR sequencing.
    Nilyanimit P; Wanlapakorn N; Niruthisard S; Pohthipornthawat N; Karalak A; Laowahutanont P; Phanuphak N; Gemma N; Poovorawan Y
    Asian Pac J Cancer Prev; 2013; 14(9):5519-25. PubMed ID: 24175852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Fast Transfer Analysis Cartridges for Cervical Sampling and Real Time PCR Based High Risk HPV Testing in Cervical Cancer Prevention - a Feasibility Study from South India.
    Vijayalakshmi R; Viveka TS; Malliga JS; Murugan K; Kanchana A; Arvind K
    Asian Pac J Cancer Prev; 2015; 16(14):5993-9. PubMed ID: 26320486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
    Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
    Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
    Gustavsson I; Aarnio R; Berggrund M; Hedlund-Lindberg J; Sanner K; Wikström I; Enroth S; Olovsson M; Gyllensten U
    Int J Cancer; 2019 Jan; 144(1):89-97. PubMed ID: 29943822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge.
    Geraets DT; van Baars R; Alonso I; Ordi J; Torné A; Melchers WJ; Meijer CJ; Quint WG
    J Clin Virol; 2013 Jun; 57(2):125-9. PubMed ID: 23518442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Fujita M; Nagashima K; Shimazu M; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Hanaoka H; Shozu M; Tsuruoka N; Kasai T; Hata A
    Int J Cancer; 2024 Sep; 155(5):905-915. PubMed ID: 38648390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.
    Cuzick J; Szarewski A; Mesher D; Cadman L; Austin J; Perryman K; Ho L; Terry G; Sasieni P; Dina R; Soutter WP
    Int J Cancer; 2008 May; 122(10):2294-300. PubMed ID: 18240149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human telomerase gene and high-risk human papillomavirus infection are related to cervical intraepithelial neoplasia.
    Zhao XY; Cui Y; Jiang SF; Liu KJ; Han HQ; Liu XS; Li Y
    Asian Pac J Cancer Prev; 2015; 16(2):693-7. PubMed ID: 25684510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
    Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
    PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.